• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常受试者和血管性血友病患者内皮组织型纤溶酶原激活物及血管性血友病因子的研究。

Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.

作者信息

Wieczorek I, Ludlam C A, MacGregor I R

机构信息

Department of Haematology, Royal Infirmary of Edinburgh, UK.

出版信息

Blood Coagul Fibrinolysis. 1994 Jun;5(3):329-34.

PMID:8075304
Abstract

Some well-described similarities exist between tissue plasminogen activator (t-PA) and von Willebrand factor (vWf) which may suggest a link in either the synthesis or release of both proteins from endothelial cells. To investigate this relationship further immunocytochemical localization of t-PA and vWf was performed in normal tissues and in skin obtained from patients with type I and type III von Willebrand's disease (vWd). Components of the fibrinolytic system were measured at baseline and after venous occlusion in healthy controls and patients with vWd. Patients with severe vWd received intravenous vWf concentrate, followed by desmopressin (DDAVP), to study the plasma response of vWf and t-PA. By immunocytochemical staining, t-PA was demonstrated in endothelial cells of normal skin, kidney and liver and also in the skin of patients with type I and type III vWd. vWf was localized in endothelial cells of all tissues except the specimens from an individual with severe vWd. Basal plasma levels of fibrinolytic components were normal in patients with vWd. Venous occlusion resulted in a rise of fibrinolytic activity in controls and patients with type I, but not type III, vWd. No rise in plasma t-PA was observed following DDAVP in severe vWd, even though near-normalization of plasma vWf levels had been obtained by prior infusion of vWf concentrate. It is concluded that the synthesis of t-PA and vWf is probably regulated by independent processes. Constitutive and regulated release of both proteins occur through different mechanisms and the basal secretion of t-PA is intact in severe vWd.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

组织型纤溶酶原激活物(t-PA)和血管性血友病因子(vWf)之间存在一些已被充分描述的相似之处,这可能暗示这两种蛋白质在内皮细胞的合成或释放过程中存在联系。为了进一步研究这种关系,对正常组织以及I型和III型血管性血友病(vWd)患者的皮肤进行了t-PA和vWf的免疫细胞化学定位。在健康对照者和vWd患者中,于基线和静脉阻塞后测量了纤溶系统的成分。重度vWd患者接受静脉注射vWf浓缩物,随后注射去氨加压素(DDAVP),以研究vWf和t-PA的血浆反应。通过免疫细胞化学染色,在正常皮肤、肾脏和肝脏的内皮细胞中以及I型和III型vWd患者的皮肤中均检测到t-PA。vWf定位于除一名重度vWd患者的标本外的所有组织的内皮细胞中。vWd患者的纤溶成分基础血浆水平正常。静脉阻塞导致对照组和I型vWd患者(而非III型vWd患者)的纤溶活性升高。在重度vWd患者中,注射DDAVP后未观察到血浆t-PA升高,尽管先前输注vWf浓缩物已使血浆vWf水平接近正常。结论是,t-PA和vWf的合成可能受独立过程调节。这两种蛋白质的组成性和调节性释放通过不同机制发生,且重度vWd患者中t-PA的基础分泌是完整的。(摘要截取自250字)

相似文献

1
Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.正常受试者和血管性血友病患者内皮组织型纤溶酶原激活物及血管性血友病因子的研究。
Blood Coagul Fibrinolysis. 1994 Jun;5(3):329-34.
2
Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.血管性血友病中血管壁对去氨加压素和静脉阻塞的分泌反应。
Acta Haematol Pol. 1994;25(3):261-8.
3
Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.血管性血友病患者对去氨加压素的纤溶反应受损。
Nouv Rev Fr Hematol (1978). 1992;34(1):55-60.
4
Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.在血管性血友病患者中,若血小板血管性血友病因子含量较低,输注去氨加压素后组织型纤溶酶原激活物(t-PA)释放受损。
Blood Coagul Fibrinolysis. 1992 Apr;3(2):149-53. doi: 10.1097/00001721-199204000-00003.
5
Blood fibrinolysis and the response to desmopressin in glomerulonephritis.肾小球肾炎中的血液纤维蛋白溶解及对去氨加压素的反应
Thromb Haemost. 1994 Jan;71(1):19-25.
6
Measurement of von Willebrand factor-specific mRNA and release and storage of von Willebrand factor from endothelial cells of dogs with type-I von Willebrand's disease.I型血管性血友病犬内皮细胞中血管性血友病因子特异性mRNA的测定以及血管性血友病因子的释放和储存
Am J Vet Res. 1995 Dec;56(12):1577-85.
7
A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.血管性血友病的一种新变体(帕多瓦I型):在所有大小的多聚体存在下,由双重结构组成的血浆血管性血友病因子寡聚体
Haematologia (Budap). 1994;26(2):97-109.
8
Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.1型和2型先天性血管性血友病患者血管性血友病因子参数对去氨加压素的反应:诊断和治疗意义
Semin Thromb Hemost. 2002 Apr;28(2):111-32. doi: 10.1055/s-2002-27814.
9
Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6.动脉内注射去氨加压素对健康志愿者和3型血管性血友病患者的局部和全身影响。白细胞介素-6的作用。
Thromb Haemost. 2000 Aug;84(2):195-203.
10
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.静脉注射去氨加压素和因子VIII-血管性血友病因子浓缩物用于治疗和预防1型、2型和3型血管性血友病患者的出血。
Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399.

引用本文的文献

1
A transcriptome analysis of basal and stimulated VWF release from endothelial cells derived from patients with type 1 VWD.1 型血管性血友病患者内皮细胞基础状态和刺激状态下 vWF 释放的转录组分析。
Blood Adv. 2023 Apr 25;7(8):1477-1487. doi: 10.1182/bloodadvances.2022007884.